NCT01529268已完成2 期
Cysteamine Bitartrate Delayed-Release for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Children (CyNCh)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)10 个研究点 分布在 1 个国家目标入组 169 人开始时间: 2012年6月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 169
- 试验地点
- 10
- 主要终点
- Improvement in Nonalcoholic Fatty Liver Disease (NAFLD)
研究概览
简要总结
CyNCh is a multi-center, placebo-controlled clinical trial of children ages 8 to 17 years with biopsy-confirmed moderate to severe nonalcoholic fatty liver disease (NAFLD). The primary objective is to evaluate whether 52 weeks of treatment with cysteamine bitartrate delayed-release capsules will result in improvement in liver disease severity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 8 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Children age 8-17 years
- •Liver biopsy obtained within 90 days of screening visit and not more than 120 days before randomization
- •Clinical history consistent with nonalcoholic fatty liver disease (NAFLD)
- •Definite NAFLD based upon liver histology
- •No evidence of any other liver disease by clinical history or histological evaluation
- •A histological severity of: NAFLD Activity Score (NAS) ≥
- •Sexually active female participants of childbearing potential (i.e., not surgically sterile [defined as tubal ligation, hysterectomy, or bilateral oophorectomy]) must agree to utilize the same two acceptable forms of contraception from screening through completion of the study and to complete a serum pregnancy test at each study visit. The acceptable forms of contraception for this study include hormonal contraceptives (oral, implant, transdermal patch, or injection) at a stable dose for at least 3 months prior to screening, and barrier (condom with spermicide, diaphragm with spermicide). Sexual activity will be ascertained at each study visit for post-menarchal females and if sexually active, subject must verify use of the same 2 acceptable forms of contraception. For pre-pubescent children, a documented attestation of abstinence from their parent or guardian will be acceptable.
- •Participants must be able to swallow DR Cysteamine tablets with the tablet intact
- •Written informed consent from parent or legal guardian
- •Written informed assent from the child
排除标准
- •There will be no exclusion criteria based on race, ethnicity or gender.
- •Participants with a current history of the following conditions or any other health issues that make it unsafe for them to participate in the opinion of the Investigators:
- •Inflammatory bowel disease (if currently active) or prior resection of small intestine
- •Heart disease (e.g., myocardial infarction, heart failure, unstable arrhythmias)
- •Seizure disorder
- •Active coagulopathy
- •Gastrointestinal ulcers/bleeding
- •Renal dysfunction with a creatinine clearance < 90 mL/min/m2
- •History of active malignant disease requiring chemotherapy within the past 12 months prior to randomization
- •History of significant alcohol intake (AUDIT questionnaire) or inability to quantify alcohol consumption
- •Chronic use (more than 2 consecutive weeks) of medications known to cause hepatic steatosis or steatohepatitis (systemic glucocorticoids, tetracycline, anabolic steroids, valproic acid, salicylates, tamoxifen) in the past year.
- •The use of other known hepatotoxins within 90 days of liver biopsy or within 120 days of randomization
- •Initiation of medications with the intent to treat NAFLD/NASH in the time period following liver biopsy and prior to randomization
- •History of total parenteral nutrition (TPN) use in year prior to screening
- •History of bariatric surgery or planning to undergo bariatric surgery during study duration
- •Clinically significant depression (patients hospitalized for suicidal ideations or suicide attempts within the past 12 months)
- •Any female nursing, planning a pregnancy, known or suspected to be pregnant, or who has a positive serum pregnancy screen.
- •Non-compensated liver disease with any one of the following hematologic, biochemical, and serological criteria on entry into protocol:
- •Hemoglobin < 10 g/dL;
- •White blood cell (WBC) < 3,500 cells/mm3 of blood;
- •Neutrophil count < 1,500 cells/mm3 of blood;
- •Platelets < 130,000 cells/mm3 of blood;
- •Direct bilirubin > 1.0 mg/dL
- •Total bilirubin >3 mg/dL
- •Albumin < 3.2 g/dL
- •International normalized ratio (INR) > 1.4
- •Poorly controlled diabetes mellitus (hemoglobin A1c (HbA1c) > 9%)
- •Evidence of other chronic liver disease:
- •Biopsy consistent with histological evidence of autoimmune hepatitis
- •Serum hepatitis B surface antigen (HBsAg) positive.
- •Serum hepatitis C antibody (anti-HCV) positive.
- •Iron/total iron binding capacity (TIBC) ratio (transferrin saturation) > 45% with histological evidence of iron overload
- •Alpha-1-antitrypsin (A1AT) phenotype ZZ or SZ
- •Wilson's disease
- •Children who are currently enrolled in a clinical trial or who received an investigational study drug within 180 days of screening or liver biopsy.
- •Subjects who are not able or willing to comply with the protocol or have any other condition that would impede compliance or hinder completion of the study, in the opinion of the investigator.
- •Failure to give informed consent
研究组 & 干预措施
DR cysteamine bitartrate capsule
Active Comparator
Active DR cysteamine bitartrate capsule
干预措施: DR cysteamine bitartrate capsule (Drug)
DR cysteamine bitartrate placebo
Placebo Comparator
Placebo DR cysteamine bitartrate capsule
干预措施: DR cysteamine bitartrate placebo (Other)
结局指标
主要结局
Improvement in Nonalcoholic Fatty Liver Disease (NAFLD)
时间窗: 52 weeks
Centrally scored and masked assessment of histologic improvement in Nonalcholic Fatty Liver Disease (NAFLD) between the baseline liver biopsy and follow-up biopsy after 52 weeks of treatment, where improvement is defined as: (1) decrease in the NAFLD Activity Score (NAS) of 2 or more and (2) no worsening of fibrosis.
次要结局
- Change in Systolic Blood Pressure(52 weeks)
- Change in Body-mass Index(52 weeks)
- Change in HOMA-IR(52 weeks)
- Steatosis: Patients With Improvement(52 weeks)
- Fibrosis: Patients With Improvement(52 weeks)
- Resolution of NASH(52 weeks)
- Change in Serum Aminotransferase and Gamma-glutamyl Transpeptidase(52 weeks)
- Change in Waist Circumference(52 weeks)
- Change in Diastolic Blood Pressure(52 weeks)
- Change in Weight (kg)(52 weeks)
- Change in Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS)(52 weeks)
- Lobular Inflammation: Patients With Improvement(52 weeks)
- Portal Inflammation: Patients With Improvement(52 weeks)
- Portal Inflammation: Change in Score(52 weeks)
- Fibrosis: Change in Stage(52 weeks)
- Change in Fasting Insulin(52 weeks)
- Hepatocellular Ballooning: Patients With Improvement(52 weeks)
- Hepatocellular Ballooning: Change in Score(52 weeks)
- Change in Body-mass Index Z-score(52 weeks)
- Change in Pediatric Quality of Life Inventory (PedsQL) Score(52 weeks)
- Steatosis: Change in Score(52 weeks)
- Lobular Inflammation: Change in Score(52 weeks)
- Change in Fasting Serum Glucose(52 weeks)
- Reduction in MRI-determined Hepatic Fat Fraction(52 weeks)
研究者
研究点 (10)
Loading locations...
相似试验
已完成
2 期
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)Ann Arbor Stage III Hodgkin LymphomaEwing Sarcoma/Peripheral Primitive Neuroectodermal TumorRecurrent Hodgkin LymphomaAnn Arbor Stage III Non-Hodgkin LymphomaLow Grade GliomaRecurrent Ewing SarcomaRecurrent Langerhans Cell HistiocytosisRecurrent Malignant GliomaRecurrent RhabdomyosarcomaRefractory Malignant GliomaRecurrent HepatoblastomaAnn Arbor Stage IV Hodgkin LymphomaRecurrent NeuroblastomaRecurrent OsteosarcomaRecurrent Primary Central Nervous System NeoplasmRecurrent Soft Tissue SarcomaRefractory NeuroblastomaRefractory Non-Hodgkin LymphomaRefractory OsteosarcomaAdvanced Malignant Solid NeoplasmAnn Arbor Stage IV Non-Hodgkin LymphomaRecurrent EpendymomaRecurrent GliomaRecurrent Non-Hodgkin LymphomaRecurrent Rhabdoid TumorRefractory Hodgkin LymphomaRefractory Langerhans Cell HistiocytosisRhabdoid TumorRecurrent Malignant Germ Cell TumorRecurrent Malignant Solid NeoplasmRecurrent MedulloblastomaRecurrent Peripheral Primitive Neuroectodermal TumorRefractory Malignant Germ Cell TumorRefractory Soft Tissue SarcomaStage IV Soft Tissue Sarcoma AJCC v7Refractory Malignant Solid NeoplasmRefractory MedulloblastomaRefractory Peripheral Primitive Neuroectodermal TumorRefractory Rhabdoid TumorStage III Soft Tissue Sarcoma AJCC v7Wilms TumorNCT03213665National Cancer Institute (NCI)20
已完成
1 期
This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With ObesityAdolescents With ObesityNCT06536023Innovent Biologics (Suzhou) Co. Ltd.36
已完成
3 期
D-cycloserine Augmentation of Cognitive Behavioral Therapy (CBT) for Pediatric Obsessive-compulsive Disorder (OCD)Obsessive-compulsive DisorderNCT01411774University of South Florida142
已完成
不适用
Randomised controlled trial (RCT) of a children's hospital at home servicePyrexia, diarrhoea, vomiting, respiratory difficultiesISRCTN11421664HS R&D Regional Programme Register - Department of Health (UK)399
已完成
2 期
An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency SyndromeGlucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)NCT02036853Adrian Lacy20